Purpose: Study design, personal persuasions, and experiences can influence willingness to participate in clinical trials (CTs). A study assessed differences between Parkinson's disease (PD) or epilepsy patients having participated in CTs and non-participants in knowledge of and attitudes toward CTs. Also considered were factors in willingness to take part and how CT participants experienced the informed consent process. Method: Random samples of members of Finland's PD (n = 2000) and epilepsy (n = 1875) patient organisations were posted a questionnaire on their views about CTs. Of the 1050 questionnaires returned, 845 met inclusion criteria. In total, 126 had participated in CTs. Results: While over 90% of respondents knew that participation is always voluntary, CT participants were more often aware that one can withdraw (p < 0.001). In both groups, most did not recognise the possibility of randomisation, and 57% in both CT participants and non-participants indicated that CTs are aimed primarily at seeking the best medication for the participant. Nevertheless, 83% of CT participants indicated ability to understand the information provided. Conclusions: While most in our study agreed that patients should be asked to participate in CTs, only 15% of subjects had done so. The discrepancy between willingness to participate and recruitment figures could be minimised by improving knowledge of CTs and communication between patients and researchers. Additionally, the groups displayed comparable false CT-related assumptions, raising questions about whether these subjects fully understood the clinical research's ultimate goal and CT participants had given true informed consent. These issues have practical and ethics implications for clinical investigators.
Introduction
Clinical trials (CTs) are necessary for the development and approval of new medical therapies. A sufficient number of potentially enrolling study participants is a critical component of high CT quality. Attitudes toward CTs are positive among the general public and in various patient groups alike [1] [2] [3] , yet recruitment of suitable patients may be challenging [4, 5] . Altruism and a desire to contribute to science are major motivating factors for participation in CTs among patients with various disorders [3, 6] . However, expectations of personal health benefits and of research providing access to health-care services are reported to be equally important factors driving participation in CTs [2, 3, 7] . Patients seem to appreciate the attention paid to them during the course of CTs, and most of them have high expectations of the therapeutic effects of the study medication [1, 2, 8] .
Before entering a CT, potential participants are required to give written informed consent for respecting their autonomy and protecting them from exploitation [9] . It can be challenging to fulfil the various elements of informed consent. The purpose and the method of CTs often differ greatly from those in standard medical treatment; for instance,
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CTs may include randomisation of the subjects, blinding of the participant and the investigator, and the use of placebo. Patients often have difficulties in understanding these issues [2, 10] . The concept of therapeutic misconception (TM) refers to a situation wherein CT participants fail to recognise the differences between clinical research and standard medical care and, hence, the requirements for informed consent are not met [11, 12] . A recent systematic review concluded that the proportion of CT participants who actually understand the individual components of informed consent ranges from 52% to 76% [10] .
Epilepsy and Parkinson's disease (PD) are neurological disorders under active clinical research. In recent years, attitudes toward CTs, motivation for participation, and understanding of study information by selected groups of patients with epilepsy or PD have been reported [2, [13] [14] [15] [16] [17] [18] . One challenge with disorders such as epilepsy and PD is that those invited to participate in a CT may include cognitively challenged subjects. Thus, comprehension of the study information can be compromised [14, 15] . Indeed, in one study, 42% of patients who had participated in a CT stated after enrolling in the 12-month trial that participation in the study was a part of the usual treatment for their disease [14] . These findings also highlight the importance of written informed consent.
We have previously assessed knowledge of and attitudes toward CTs in two large populations of patients with epilepsy [19] or PD [20] . Both patient groups included subjects who had participated in CTs. The aim of the study was to compare knowledge of and attitudes toward CTs, alongside issues related to TM, between members of the two populations: patients who had taken part in a CT and those who had not. Furthermore, we examined issues affecting willingness to participate in clinical drug trials and how CT participants had experienced the process related to informed consent.
Methods

The study sample
The subjects in the study consisted of a random sample of members of patient organisations who have epilepsy (n = 1875, from a membership base of 7500) or PD (n = 2000, from a total association membership of 8000). The patient organisations were the Finnish Epilepsy Association (FEA), which is the Finnish chapter of the International Bureau for Epilepsy, and the Finnish Parkinson Association (FPA). The lists of patients to whom the material was to be sent were generated by the FEA and FPA via randomisation, in which every fourth person on the member list was selected. The study information sheet and covering letter, sent to the subjects identified, requested a response from only adults with a diagnosis of epilepsy or PD who were able to give responses independently. A breakdown of the data-gathering process applied in the study is shown in Fig. 1 . In total, 1050 questionnaires were returned for a response rate of 27%.
The study was conducted in compliance with the Declaration of Helsinki, and a favourable opinion of the study was obtained from the Research Ethics Committee of the University of Eastern Finland. The study was also approved by the Executive Board of the FEA and of the FPA. Moreover, the FEA and FPA staff sent the study questionnaires to the participants in order to ensure their privacy. The investigators did not have access to the study population's personal data, and the responses to the questionnaire were given anonymously.
The data
The data for the study were obtained via a questionnaire developed for the purposes of our previous studies [19, 21] . In brief, the questionnaire, which was to be selfadministered by the patients, was based on previous literature [22, 23] and pilot testing among patients with PD (n = 12). The first part of the questionnaire covered data on demographic and socio-economic matters, along with clinical aspects of epilepsy or PD and its treatment. The second part formed the actual survey instrument, which featured 50 items addressing elements such as knowledge of and attitudes toward CTs, factors associated with willingness to participate in CTs, and experiences of the informed consent process. The subjects responded to each item's statement by using a five-option Likert scale, where the options were 'strongly disagree' [1] , 'disagree' [2] , 'cannot say' [3] , 'agree' [4] , and 'strongly agree' [5] .
Statistical analysis
The data were analysed by means of the SPSS Statistics 21.0 statistical analysis software. The background information was characterised in terms of frequency and percentage distributions. Frequencies, means, and standard deviations (SDs) were used to describe the CT participants' and non-participants' attitudes and knowledge of CTs, motivation for participation / potential participation, and expectations of personal health benefits. For clearer presentation of the results, agreement and disagreement categories were formed by combining the 'agree' and 'strongly agree' responses and the 'disagree' and 'strongly disagree' responses, respectively. Pearson's chi-squared test was used to determine differences in clinical variables between CT participants and non-participants. A non-parametric Mann-Whitney U test was used to determine differences between CT participants and non-participants for the statements. The results were considered statistically significant at p < 0.05. 
Results
All in all, 126 (15%) of the respondents had participated in a CT (referred to as CT participants below), and the remaining 719 (85%) had not (hereinafter they are denoted as non-participants). Significant differences were not observed between CT participants and non-participants in age band (p = 0.510), gender (p = 0.168), or education (p = 0.342) (see Table 1 ).
General attitudes and willingness to participate among CT participants and non-participants
In general, both CT participants and non-participants held positive attitudes toward CTs (see Table 2 ). Over 80% of respondents in both groups indicated that they would participate in CTs to help other patients with epilepsy or PD. The use of placebo control and risk of severe adverse effects were associated with decreased willingness to participate in a CT in both groups. A significant difference was observed between CT participants and non-participants in willingness to participate in a comparative trial.
Knowledge of the issues related to clinical trials among participants and non-participants
Overall, the respondents were well aware of general aspects of CTs, such as the voluntary nature of participation and informed consent (see Table 3 ). However, a lower proportion of non-participants than CT participants were aware of the right to withdraw from a CT. Fewer than half of the subjects in each group recognised the possibility of random allocation of treatment in CTs.
Respondents' expectations of personal health benefits related to clinical trials
There were no significant differences in responses between CT participants and non-participants with respect to expectations of personal health benefits, except that a higher proportion of non-participants than CT participants thought that a CT physician is aware of whether the participant is receiving a new drug vs. a placebo. Almost 60% of the respondents in both groups failed to recognise that CTs are not primarily aimed at seeking the best medication for the research participants (see Table 4 ). 
Views about the informed consent process
Overall, the informed consent process was perceived mainly positively by the 126 respondents who had participated in a CT. In total, 80% of them stated they were able to concentrate on the information about the trial, and just over 80% indicated they had understood this information. Of the full group of respondents, 85% agreed they had been given enough time for the decisionmaking. Clinical trial participants trusted that their personal data were handled confidentially. However, nearly 80% agreed consent ought to be asked for again if the data are to be used in an additional study (see Fig. 2 ).
Discussion
Several works reporting on attitudes toward and experiences of participation in CTs among patients with PD or epilepsy have been published [2, [13] [14] [15] [16] [17] [18] . To the best of our knowledge, however, ours is the first large-scale survey to assess how a random sample of CT participants and non-participants among patients with PD or epilepsy perceive CTs and to gauge the differences between the two groups.
Attitudes toward CTs were mainly positive and nearly identical between those who had participated in a CT and those who had not. Also, most respondents concluded that patients should be asked to participate in CTs for the development of new therapies. In both the CT participant and non-participant group, interest in taking part in placebo-controlled trials was rather low, as was that in trials with a risk of severe adverse effects. Prior work has identified both issues as significant barriers to participation in CTs [1, 2, [24] [25] [26] .
There were statistically significant differences in knowledge of general issues related to CTs between CT participants and non-participants in areas such as the overall concept of CTs, the necessity of CTs for the approval of new drugs, the right to withdraw from a CT, and the sponsoring of CTs (see Table 3 ). These findings suggest that information given to CT participants prior to and during the trials had increased their knowledge and understanding of participants' rights and their awareness that trials must be done before a drug can enter the market. It is encouraging to note that both groups were well aware of the voluntary nature of participation and the need for informed consent in CTs. However, only approximately 40% of the CT participants, a proportion similar to that among non-participants, were aware that trials might include procedures different from those used in standard medical care, such as randomisation. Between 40% and 50% of the subjects in both groups held the fundamentally erroneous opinion that the investigator is able to choose the study treatment for the participant or at least is aware of the given treatment.
More than 90% of both the CT participants and non-participants recognised that the essential goal for CTs is to find better treatment for future patients. However, almost 60% of the subjects in both of the groups also indicated that CTs are aimed primarily at finding the best treatment for the trial participant. Furthermore, 60-65% of the subjects in both groups stated that they would participate in a CT because they would receive the best treatment for them and that participation would offer them better means of monitoring their health problem than standard treatment does. Expectations of personal health benefits are a major motivating factor in participation in research, as previously found within patients with PD, epilepsy, and other disorders 17, 18] . In general, participation in research is considered a means of access to health services [3, 7] . Strong motives linked to personal benefits are considered a risk factor for TM. Therapeutic misconception may lead to overestimation of benefits, underestimation of the risk of harm, and/or under-appreciation of alternatives to participation in CTs [12, 27] .
A higher proportion of CT participants than of non-participants in our study indicated that they would take part in a CT only if their own physician were the investigator; however, this difference was not statistically significant. Also, continuation of the physician-patient relationship was slightly more important as a motivating factor in the CT participants group. Furthermore, it has been suggested that having one's personal doctor as the investigator may blur the line between standard treatment and research, leading to a risk of TM [28, 29] . A critical issue that arises is how TM may affect the informed consent process; i.e., is consent valid when the study participant holds false beliefs [11] . Evaluation of TM is a complicated task, and there is still disagreement about its definition and how to measure it [30, 31] . The possibility and prevalence of TM usually are assessed in patients recruited to CTs; however, patients potentially eligible for CTs may have preconceptions of the benefits and the methods related to CTs before actual recruitment for a trial. These preconceptions, which may vary with individual-specific health problems, might, in turn, predispose them to TM.
Our study and previous research have shown that patients who have participated in CTs express a high degree of satisfaction with the informed consent process as a whole and also with the information they have received. In previous studies, most of the PD patients taking part reported that they understood the key components of the informed consent process. [2, 14] . To our knowledge, no such data are available for patients with epilepsy. About 20% of our CT participant respondents, however, indicated that they would have wanted an opportunity to ask more about the trial. Moreover, about 20% felt that they did not understand the information given or that their opinion was not respected. Over 80% of our respondents considered the person who recruited them for the CT to have had proper knowledge of the trial and stated that they had been given enough time to make the decision. Generally, patients seemed to be satisfied with the time given for the decision [1] . Participants' understanding depends, in addition to their competence, on the duration of the informed consent process and on the explanation skills of the researchers [10] . As for future trials, three quarters of our CT participant subjects concluded that new consent should be sought if the CT data were to be used for other research purposes. This issue has been given attention globally and remains under debate [32, 33] .
Our study has some limitations. Firstly, the response rate (27%) was quite modest. However, the number of survey forms (n = 845) proved to be sufficient for statistical evaluations. Also, the subjects in the study represented a random sample of members of the FEA or FPA, and the age and sex distribution of the subjects corresponded well to those of the general patient populations for the disorders in question. In the interest of privacy, the list of study subjects was generated by the FEA and FPA, and the survey forms were returned anonymously. Therefore, the authors were unable to contact those who did not respond. Furthermore, we were not able to confirm the diagnoses of respondents. However, in Finland a diagnosis of epilepsy and PD always requires assessment by either a neurologist or, in the case of elderly subjects, a geriatrician. An issue to consider is the questionnaire, which was developed for a study among patients with epilepsy [19] and then modified in light of the feedback from those patients and also after pilot testing with PD patients. However, the questionnaire was not validated statistically or against in-depth interviews of the subjects. Considering the attitudes, knowledge, and views of the subjects who had participated in CTs, it should be noted that the authors have no information on the time between participation and the questionnaire or on what kind of CT the subjects had taken part in. These issues may introduce a risk of recall bias.
Conclusion
Although most respondents in our study agreed that patients with epilepsy or PD should be asked to take part in CTs, only 15% of the subjects had actually participated in such trials. This gulf between willingness to participate in CTs and recruitment of enough patients in practice, which manifests well-recognised problems, could be minimised by improving knowledge and understanding of CTs and also by a more thorough communication between patients and those conducting the research [25] . Our finding that subjects who had taken part in CTs showed only slightly better knowledge of the general issues related to CTs than did those who had not participated highlights the need for better understanding. Additionally, the two groups displayed comparable false assumptions related to the goals and methods of CTs -a feature that is associated with TM. It is essential for CT participants to understand that the purpose of research is to generate generalisable knowledge and not necessarily to guarantee personal therapeutic benefit [34] . Although the CT participants in our study were satisfied with the informed consent process, our results raise questions as to whether these subjects fully understood the ultimate goal of the clinical research and whether the informed consent was valid. These issues have both ethics-linked and practical implications for clinical investigators.
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